Kurma Partners has closed its fourth biotech venture capital fund after raising 215 million euros ($252 million) to support ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

As Sanofi counts down the days before its new leader arrives, the French pharma’s interim CEO acknowledged there had been a ...

While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce Biotech why the ...

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

A pair of Sage Therapeutics veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage ...

Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), ...

McKesson let go of a minority share of its medical/surgical solutions division for $1.25 billion to Apollo Funds as part of ...

Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s ...

Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis (RMS) trials, revealing that deaths from ...

National Cancer Institute Director Anthony Letai, M.D., Ph.D., has attempted to fight back against the “misinformation” ...